80 likes | 214 Views
Hansen Online figure 1. 40. GAPDH. LANA. 30. Threshold Cycle. 20. 10. KS 330. KS 602. Skin P1. Skin P2. Skin P3. KS 248. KS 606. KS P2. Skin. Kaposi sarcoma. Skin. KS. Skin. KS. Skin. KS. A. B. Hansen Online figure 1 Cont. 10. 8. 6. 4. 2.
E N D
Hansen Online figure 1 40 GAPDH LANA 30 Threshold Cycle 20 10 KS 330 KS 602 Skin P1 Skin P2 Skin P3 KS 248 KS 606 KS P2 Skin Kaposi sarcoma Skin KS Skin KS Skin KS A B
Hansen Online figure 1 Cont. 10 8 6 4 2 Delta Ct (K12-miR Ct - RNU66 Ct) 0 -2 -4 -6 -8 -10 -12 K12-3 K12-7 K12-12 K12-5 K12-9 K12-3* K12-9* KS biopsy Skin C
Hansen Online figure 2 pSIN K12-6-5p K12-11 0ng Cluster Individual lentivirus ** 6 6 250ng Cluster ** Cluster 500ng Cluster 4 2 *** 2 microRNA Delta Ct -2 * 0 Delta (K12-miR Ct- RNU66 Ct) -6 -2 1.2 -4 1 -6 * 0.8 -8 * 0.6 * * Relative RLU:PRO normalized to 0ng Cluster * -10 ** 0.4 * K12-10a K12-3 K12-1 K12-2 K12-7 K12-5 K12-8 K12-9 K12-11 K12-12 K12-9* K12- 3* K12-4-3p K12-6-3p K12-4-5p K12-6-5p ** ** 0.2 ** * ** ** B * ** * ** ** 0 0ng Cluster K12-1 K12-3 K12-4-3p K12-5 K12-6-3p K12-7 K12-8 K12-9 K12-11 miRNA Reporter Construct A C
D Hansen Online figure 2 Cont. A G C MAF-582bp 5’ 3’ K12-6-3p 3’ 5’ MAF-1566bp 5’ 3’ K12-4-5p 3’ 5’ MAF-1748bp 5’ 3’ K12-11 3’ 5’ I I I I : : : I I I I I I I I 5’ 3’ MAF-2019bp C U C A C U C C U U C U C A A C C C A U C U K12-1 3’ 5’ G A G U U G U C G G G C U U U U G G U A G U MAF-2638bp 5’ 3’ G U A U U G A A A A C C A A A G U A U U A A : I I I I I I : I I I I I K12-6-3P 3’ 5’ A G C C U G U G U C C G A U U C G U A A U U G C G 5’ 3’ MAF-2738bp G U C U A G C U G G G C C U G A U G U C A A K12-2 3’ 5’ I : I : : : I I I I I I I I C G C U U G C C U U U U C A C U A A A G U U A G C 5’ 3’ MAF-3425bp U G C A G A A C U G G A U U U U C U G U A A C : I I : : I I I : I I I I I I K12-6-5p 3’ 5’ C G A A U G U G G G U C A A A G G A C A U U A C U G A U C A G G A G C A A A G C C A U C C I I I I I I I I I : I I I I I I MAF-3723bp 5’ 3’ G A G U U G U C G G G C U U U U G G U A G U A G C C U G U G U C C G A U U C G U A A U U : I : : I I I I I I I I K12-6-3P C C G U A C C U A A U C C A C G A C G A C C 3’ 5’ G U U G U G U A G A A U U A A G C A U U U U I I I : I I I I I I I I I I I A G G U U G U G U U U G G U G C U G C U A A U G G C U A G U U U U U G A U A C C G A G A G A C A U A U A U G U C G A G U U C A U G U 5’ 3’ MAF-3850bp : : I I I I I : I I I I : I : I I I I I I I I I I G A G U U G U U A G C U A C U G U G A G A C A U A U A U A U A G A G U U C A A G U U C A K12-11 3’ 5’ G G A U C U C A U G A C G C C A A A U C G A : : I I I I I I I I I I I A A A G A G U U A G G U C U G U U U A G C U 5’ 3’ MAF-4350bp K12-6-3p 3’ 5’
Hansen Online figure 2 Cont. 1.6 1.4 1.2 1 * * Relative MAF mRNA levels .8 .6 .4 .2 0 pSIN K12-1 K12-2 K12-4 K12-5 K12-6 K12-7 K12-8 K12-10 K12-11 K12-9 E
Hansen Online figure 3 1.2 1 7 0.8 ** 6 0.6 Relative MAF mRNA levels 5 0.4 4 Relative MAF mRNA levels 0.2 3 0 ** pCDNA Cluster 2 1 0 Cluster NTC Cluster i11 Cluster i6 7 6 5 4 Relative MAF mRNA levels 3 2 1 0 pCDNA NTC pCDNA i11 pCDNA i6 A B C *
Hansen Online figure 4 siControl siMAF 3 ** * 2 * ** Relative mRNA levels 1 ** 0 MAF MAML2 FLT1 CXCR4 CXCL12 A B
Hansen Online figure 5 10 8 6 Relative mRNA levels normalized to LEC 4 2 0 LEC MAF FLT4 LYVE FLT1 PDPN TFEC CXCR4 NRCAM PROX1 HDAC9 SLC1A1 GULP1 CXCL12 ITGB3 LEC markers BEC markers A B